Verena Schlintl

发表

Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

R. Greil, F. Huemer, L. Weiss, 2021, Journal of gastrointestinal oncology.

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy

R. Greil, F. Huemer, A. Kirilovsky, 2020, Journal of clinical medicine.